What Is DSIP? Benefits, Research & Safety

DSIP was discovered in 1977 by a Swiss research group led by Monnier and Schoenenberger. They were investigating sleep-promoting factors in the blood of sleeping rabbits and isolated a peptide that could induce delta wave (deep, slow-wave) sleep when injected into the brains of awake rabbits. The peptide was subsequently characterised as a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was found to be present in various mammals, including humans. Throughout the 1980s and 1990s, research expanded to explore DSIP's effects beyond sleep. Studies revealed potential applications in stress protection, pain management, and treatment of various conditions. DSIP was used clinically in some European countries, particularly Switzerland and Germany. Research results, however, have been variable. While some studies showed promising effects, others failed to replicate findings. This inconsistency has complicated the clinical development pathway. Interest in DSIP has continued, particularly in research settings exploring its mechanisms of action and potential applications. It remains an intriguing neuropeptide with effects that extend beyond its original sleep-inducing characterisation.